methocarbamol sold brand name robaxin among others medication used shortterm musculoskeletal may used together rest physical therapy pain less preferred low back limited use rheumatoid arthritis cerebral effects generally begin within half taken mouth injection common side effect include headaches sleepiness serious side effects may include anaphylaxis liver problems confusion use recommended pregnancy risk injury skeletal muscle relaxants generally avoided geriatric methocarbamol centrally acting muscle works unclear appear affect muscles methocarbamol developed laboratories h robins later acquired pfizer studies directed towards development propanediol derivatives possessed muscle relaxant properties superior mephenesin low potency short duration approved medical use united states available generic relatively inexpensive commonly prescribed medication united states million methocarbamol muscle relaxant used treat acute painful musculoskeletal spasms variety musculoskeletal however limited inconsistent published research medications efficacy safety treating musculoskeletal conditions primarily neck back methocarbamol injection may beneficial effect control neuromuscular spasms however replace current treatment useful chronic neurological disorders cerebral palsy currently suggestion muscle relaxants may improve symptoms rheumatoid arthritis however insufficient data prove effectiveness well answer concerns regarding optimal dosing choice muscle relaxant adverse effects functional clinical effectiveness methocarbamol compared muscle relaxants one trial methocarbamol versus cyclobenzaprine wellstudied muscle relaxant localized muscle spasm found significant differences effects improved muscle spasm limitation motion limitation daily contraindications methocarbamol include methocarbamol centrally acting skeletal muscle relaxant significant adverse effects especially central nervous potential side effects methocarbamol include product label states methocarbamol cause jaundice minimal evidence suggest methocarbamol causes liver clinical trials methocarbamol laboratory measurements liver damage indicators serum transaminase astalt levels confirm although unlikely impossible rule methocarbamol may cause mild liver injury skeletal muscle relaxants associated increased risk injury among older methocarbamol appeared less sedating muscle relaxants notably cyclobenzaprine similar increased risk methocarbamol cited along muscle relaxants beers criteria poorly tolerated older adults anticholinergic adverse effects sedation increased risk fractures noting effectiveness dosages tolerated older adults methocarbamol labeled fda pregnancy category c teratogenic effects medication known given pregnant women clearly limited information available acute toxicity overdose observed frequently conjunction cns depressants alcohol benzodiazepines symptoms nausea drowsiness blurred vision hypotension seizures reported deaths overdose methocarbamol alone presence cns unlike carbamates meprobamate prodrug carisoprodol methocarbamol greatly reduced abuse studies comparing benzodiazepine lorazepam antihistamine diphenhydramine along placebo find methocarbamol produces increased liking responses sedativelike effects however higher doses dysphoria considered abuse profile similar weaker methocarbamol may inhibit effects pyridostigmine therefore methocarbamol used caution myasthenia gravis taking anticholinesterase methocarbamol may disrupt certain screening tests cause color interference laboratory tests acid urinary testing vanillylmandelic acid vma using gitlow mechanism action methocarbamol currently effect thought localized central nervous system rather direct effect skeletal effect motor end plate peripheral nerve efficacy medication likely related sedative alternatively methocarbamol may act via inhibition acetylcholinesterase similarly healthy individuals plasma clearance methocarbamol ranges mean plasma elimination halflife ranges hours plasma protein binding ranges elimination halflife longer elderly kidney problems liver methocarbamol carbamate derivative guaifenesin produce guaifenesin metabolite carbamate bond hydrolyzed metabolism phase ring hydroxylation odemethylation followed phase ii major metabolites unhydrolyzed small amounts unchanged methocarbamol also excreted methocarbamol approved muscle relaxant acute painful musculoskeletal conditions united states muscle relaxants widely used treat low back pain one frequent health problems industrialized countries currently million prescriptions filled methocarbamol orphenadrine used us emergency department visits lower back pain united states low back pain fifth common reason physician visits second common symptomatic primary care visits low back pain least one medication prescribed initial office visit one third prescribed two commonly prescribed drugs low back pain included skeletal muscle cyclobenzaprine methocarbamol us medicare formulary may account higher use generic formulation medication relatively inexpensive costing less alternative metaxalone methocarbamol without ingredients sold brand name robaxin uk us south africa marketed lumirelax france ortoton germany many names combination active ingredients sold names acetaminophen paracetamol trade names robaxacet tylenol body pain night ibuprofen robax platinum acetylsalicylic acid robaxisal us however spain tradename robaxisal used paracetamol combination instead robaxacetcitation needed combinations also available independent manufacturers generic namescitation needed although opioids typically first line treatment severe pain several trials suggest methocarbamol may improve recovery decrease hospital length stay muscles spasms associated rib however methocarbamol less useful treatment acute traumatic pain longterm studies evaluating risk development cancer using methocarbamol currently studies evaluating effect methocarbamol mutagenesis safety efficacy methocarbamol established pediatric individuals age except httpsenwikipediaorgwikimethocarbamol